MCID: ESP002
MIFTS: 51

Esophageal Varix

Categories: Cardiovascular diseases, Gastrointestinal diseases, Rare diseases

Aliases & Classifications for Esophageal Varix

MalaCards integrated aliases for Esophageal Varix:

Name: Esophageal Varix 12 29 15
Esophageal Varices 12 73 20 54 15 17
Bleeding Esophageal Varices 12 54 70
Esophageal Varices in Disease Classified Elsewhere, with Bleeding 12
Esophageal Varices with Bleeding in Disease Ec 12
Esophageal Varices Without Mention of Bleeding 12
Esophageal Varices Without Bleeding 12
Esophageal Varices with Bleeding 12
Bleeding Oesophageal Varices 12

Classifications:



External Ids:

Disease Ontology 12 DOID:112
ICD9CM 34 456.0 456.2 456.20
NCIt 50 C78282
ICD10 32 I85.01
UMLS 70 C0155789 C0155791 C0155792

Summaries for Esophageal Varix

MalaCards based summary : Esophageal Varix, also known as esophageal varices, is related to portal vein thrombosis and schistosomiasis. An important gene associated with Esophageal Varix is SST (Somatostatin), and among its related pathways/superpathways are Complement and coagulation cascades and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Ethiodized oil and Somatostatin have been mentioned in the context of this disorder. Affiliated tissues include liver, spleen and kidney, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia : 73 Esophageal varices are extremely dilated sub-mucosal veins in the lower third of the esophagus. They are... more...

Related Diseases for Esophageal Varix

Diseases related to Esophageal Varix via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 588)
# Related Disease Score Top Affiliating Genes
1 portal vein thrombosis 31.1 SERPINC1 F2 AFP
2 schistosomiasis 31.0 GPT F2 ALB
3 hepatitis b 30.9 GPT F2 ALB AFP
4 hepatorenal syndrome 30.7 GPT F2 ALB
5 primary biliary cholangitis 30.7 GPT F2 CP ALB
6 peliosis hepatis 30.6 GPT F2 AFP
7 peptic ulcer disease 30.5 SST ATP4A ATP12A
8 endocarditis 30.5 SERPINC1 F2 ALB
9 peptic esophagitis 30.5 ATP4A ATP12A ALB
10 alcoholic hepatitis 30.5 GPT F2 ALB
11 disseminated intravascular coagulation 30.4 SERPINC1 GPT F3 F2
12 hypersplenism 30.4 THPO SERPINC1 GPT F2 ALB
13 autoimmune hepatitis 30.4 GPT F2 ALB
14 biliary atresia 30.3 GPT F2 ALB
15 acute cholangitis 30.3 GPT F2 ALB
16 pleural empyema 30.3 GPT F2 ALB
17 hernia, hiatus 30.3 ATP4A ATP12A
18 obstructive jaundice 30.3 GPT F2 ALB
19 dieulafoy lesion 30.3 F2 ATP4A ATP12A
20 bile reflux 30.2 ATP4A ATP12A ALB
21 aortic valve insufficiency 30.2 F3 F2 ALB
22 factor viii deficiency 30.2 SERPINC1 F3 F2 ALB
23 esophageal candidiasis 30.2 ATP4A ATP12A
24 hepatic encephalopathy 30.2 SST GPT F2 ALB
25 microinvasive gastric cancer 30.2 ATP4A ATP12A AFP
26 mitral valve stenosis 30.2 SERPINC1 F3 F2
27 cholangitis, primary sclerosing 30.2 SERPINA1 GPT F2 ALB AFP
28 alcoholic liver cirrhosis 30.2 INS GPT F2 ALB AFP
29 protein s deficiency 30.2 SERPINC1 F3 F2
30 diarrhea 30.2 SST SERPINA1 GPT ALB
31 hemophilia b 30.1 SERPINC1 F3 F2
32 budd-chiari syndrome 30.1 SERPINC1 F3 F2 ALB AFP
33 tricuspid valve insufficiency 30.1 GPT F3 F2 ALB
34 duodenitis 30.1 INS ATP4A ATP12A ALB
35 giant hemangioma 30.1 SERPINC1 F3 F2 AFP
36 pulmonary embolism 30.1 SERPINC1 F3 F2 ALB
37 cholangitis 30.0 HP GPT F3 F2 ALB
38 angiodysplasia 30.0 SST F3 ATP4A ATP12A
39 aspiration pneumonitis 30.0 F3 ATP4A ATP12A ALB
40 sclerosing cholangitis 30.0 HP GPT F2 ALB
41 cholestasis 30.0 SERPINA1 GPT F2 CP ALB
42 sleep apnea 30.0 INS GPT ALB
43 respiratory failure 30.0 SERPINA1 GPT F3 F2 ALB
44 hepatic veno-occlusive disease 30.0 THPO SERPINC1 F3
45 hyperthyroidism 30.0 SST INS GPT ALB
46 constrictive pericarditis 29.9 SERPINA1 ALB
47 active peptic ulcer disease 29.9 SST F3 F2 ATP4A ATP12A ALB
48 non-alcoholic steatohepatitis 29.9 INS GPT ALB
49 neutropenia 29.8 THPO GPT CP ALB
50 hepatic coma 29.7 SERPINC1 GPT F3 F2 ALB AFP

Comorbidity relations with Esophageal Varix via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Alcoholic Liver Cirrhosis Deficiency Anemia
Esophageal Disease Esophagitis
Heart Disease Hepatic Encephalopathy
Portal Hypertension

Graphical network of the top 20 diseases related to Esophageal Varix:



Diseases related to Esophageal Varix

Symptoms & Phenotypes for Esophageal Varix

MGI Mouse Phenotypes related to Esophageal Varix:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.07 AFP ALB ATP12A ATP4A BCHE CP
2 immune system MP:0005387 9.9 ALB ATP4A CP F2 F3 HP
3 digestive/alimentary MP:0005381 9.87 ALB ATP12A ATP4A F2 INS PKHD1
4 liver/biliary system MP:0005370 9.5 AFP ALB CP HP INS PKHD1
5 mortality/aging MP:0010768 9.44 AFP ALB ATP4A BCHE CBX8 F2

Drugs & Therapeutics for Esophageal Varix

Drugs for Esophageal Varix (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 63)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
2
Somatostatin Approved, Investigational Phase 4 51110-01-1, 38916-34-6 53481605
3
Terlipressin Approved, Investigational Phase 4 14636-12-5 72081
4
Pantoprazole Approved Phase 4 102625-70-7 4679
5
Octreotide Approved, Investigational Phase 4 83150-76-9 383414 6400441
6
Propranolol Approved, Investigational Phase 4 525-66-6 4946
7
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
8 Hormones Phase 4
9 Hormone Antagonists Phase 4
10 Vasoconstrictor Agents Phase 4
11 Retinol palmitate Phase 4
12 retinol Phase 4
13 Antacids Phase 4
14 Anti-Ulcer Agents Phase 4
15 Vasodilator Agents Phase 4
16 Adrenergic Antagonists Phase 4
17 Adrenergic beta-Antagonists Phase 4
18 Adrenergic Agents Phase 4
19 Neurotransmitter Agents Phase 4
20 Antihypertensive Agents Phase 4
21 Anti-Arrhythmia Agents Phase 4
22 Antineoplastic Agents, Hormonal Phase 4
23 Gastrointestinal Agents Phase 4
24 Proton Pump Inhibitors Phase 4
25
Rifaximin Approved, Investigational Phase 3 80621-81-4 6436173 46783403
26
Timolol Approved Phase 3 26839-75-8 33624 5478
27
Ethanolamine oleate Approved Phase 3 2272-11-9
28
Nadolol Approved Phase 3 42200-33-9 39147
29
Maleic acid Experimental Phase 3 110-16-7 444266
30
Vapreotide Experimental, Investigational Phase 3 103222-11-3 23725064
31 Anti-Bacterial Agents Phase 3
32 Anti-Infective Agents Phase 3
33 Hemostatics Phase 3
34 Ulipristal acetate Phase 3 126784-99-4
35 Analgesics Phase 3
36 Fibrin Tissue Adhesive Phase 3
37 Coagulants Phase 3
38 Pharmaceutical Solutions Phase 3
39 Sclerosing Solutions Phase 3
40
Scopolamine Approved, Investigational 51-34-3, 6533-68-2 5184
41
Rabeprazole Approved, Investigational 117976-89-3 5029
42
tannic acid Approved 1401-55-4
43
Warfarin Approved 81-81-2 6691 54678486
44
Benzocaine Approved, Investigational 1994-09-7, 94-09-7 2337
45
Heparin Approved, Investigational 9005-49-6 772 9812414
46
Simvastatin Approved 79902-63-9 54454
47
Polidocanol Approved 9002-92-0
48
Entecavir Approved, Investigational 142217-69-4 153941
49
Adefovir dipivoxil Approved, Investigational 142340-99-6 60871
50
Lamivudine Approved, Investigational 134678-17-4 60825

Interventional clinical trials:

(show top 50) (show all 81)
# Name Status NCT ID Phase Drugs
1 Banding Ligation Plus Propranolol Versus Banding Ligation to Prevent Rebleeding of Esophageal Varices Unknown status NCT02740166 Phase 4 propranolol
2 Prevention of Esophageal Variceal Rebleeding Unknown status NCT00863837 Phase 4 terlipressin (vasoconstrictor);pantoloc (proton pump inhibitor)
3 Endoscopic Treatment of Esophageal Varices in Advanced Liver Disease Patients: a Randomized Controlled Trial Comparing Band Ligation and Cyanoacrylate Injection Completed NCT00799851 Phase 4 cyanoacrylate injection
4 Appropriate Time Interval for Repeat Sessions of Endoscopic Ligation for the Eradication of Esophageal Varices Completed NCT01291277 Phase 4
5 Efficacy And Safety Of Terlipressin Vs Octreotide As Adjuvant Therapy In Bleeding Esophageal Varices Completed NCT00534677 Phase 4 Terlipressin;Octreotide
6 A Randomized, Controlled, Multicentric Trial Comparing Endoscopic Band Ligation Versus Ransjugular Intrahepatic Portosystemic Stent Shunt in Cirrhotic Patients With Recurrent Variceal Bleeding Non Responding to Medical Therapy Completed NCT00570973 Phase 4
7 A Randomized, Controlled Trial of Ligation Plus Vasoconstrictor vs.Ligation Plus Proton Pump Inhibitor in the Control of Acute Esophageal Variceal Bleeding Completed NCT01112852 Phase 4 pantoloc 40 mg;somatostatin or terlipressin
8 Hemodynamic Effects of Terlipressin and High Dose Octreotide on Patients With Liver Cirrhosis Related Esophageal Varices: A Randomized, Placebo-controlled Multicenter Trial Completed NCT02119884 Phase 4 Terlipressin;Octreotide
9 PROPRANOLOL ASSOCIATED WITH ENDOSCOPIC BAND LIGATION REDUCES RECURRENCE OF ESOPHAGEAL VARICES FOR PRIMARY PROPHYLAXIS OF VARICEAL BLEEDING?: A RANDOMIZED CONTROLLED TRIAL Completed NCT01893541 Phase 4 PROPRANOLOL
10 RCT for the Effect of Early Administration of Vasoactive Substances When Combined With Endoscopic Treatment in Acute Gastro-esophageal Variceal Bleeds: Comparisons Among Terlipressin, Somatostatin, and Octreotide Completed NCT00966355 Phase 4 Terlipressin;Somatostatin;Octreotide
11 Short-course Somatostatin Versus Terlipressin Infusion in Combination With Endoscopic Variceal Ligation for the Prevention of Early Esophageal Variceal Rebleeding Completed NCT02757703 Phase 4 Somatostatin;Terlipressin;Pantoprazole
12 Comparison of 24-hours Versus 72-hours of Octreotide Infusion Along With Endoscopic Therapy in Preventing Early Rebleed From Esophageal Varices: a Multi-center, Randomized Clinical Study Recruiting NCT03624517 Phase 4 Octreotide
13 Endoscopic Treatment Versus Propranolol for Primary Prevention of Patients With Hepatocellular Carcinoma and Concomitant Esophageal Varices Recruiting NCT01970748 Phase 4 Propranolol
14 Impact of Nonselective Beta-blocker on Acute Kidney Injury in Cirrhotic Patients With Esophageal Varices Recruiting NCT04074473 Phase 4 propranolol
15 RCT Comparing the Efficacies of Endoscopic Band Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding in Patients With Previous Endoscopic Variceal Treatment Recruiting NCT00966082 Phase 4
16 RCT Comparing the Efficacies of Endoscopic Variceal Ligation (EBL) and Combined Treatment of Beta-blocker and EBL for the Prevention of Esophageal Variceal Rebleeding Recruiting NCT00966121 Phase 4
17 Effect of Administration "Add on" of Rifaximin on Portal Hypertension of Patients With Liver Cirrhosis and Esophageal Varices in Standard Therapy With Propranolol Unknown status NCT02508623 Phase 3 Rifaximin;Placebo
18 Hemodynamic Response of Rifaximin and Non-selective β-blocker Combination Therapy Versus Non-selective β-blocker Monotherapy in Cirrhotic Patients With Esophageal Varices Unknown status NCT01897051 Phase 2, Phase 3 Rifaximin + propranolol;Propranolol + Placebo
19 Control of Acute Variceal Bleeding Using the Multi-shooter Band Ligator Compared to Injection Sclerotherapy. Completed NCT01131962 Phase 3
20 Randomized, Double-Blind Study of Timolol (A Nonselective Beta-Adrenergic Blocker) vs Placebo to Prevent Complications of Hepatic Portal Hypertension in Patients With Cirrhosis Completed NCT00006398 Phase 3 Timolol Maleate;Placebo
21 Comparison of Endoscopic Variceal Ligation (EVL) and Propranolol in Secondary Prophylaxis of Variceal Bleeding in Patients With Non Cirrhotic Portal Hypertension (NCPH): A Prospective Randomized Controlled Trial Completed NCT01000779 Phase 3 Propranolol
22 Esophageal Stent is More Effective Than Tamponade Controlling Refractory Esophageal Variceal Bleeding: a Randomized Controlled Trial Completed NCT01242280 Phase 3
23 The Early Use of Sanvar® With Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension Completed NCT00331188 Phase 3 Sanvar® (vapreotide)
24 Danish Carvedilol Study in Portal Hypertension. Carvedilol in the Prevention of Bleeding in Portal Hypertension and Esophageal Varices Completed NCT00493480 Phase 3 carvedilol;propranolol
25 Prospective Randomized Study on the Efficacy of Endoscopic Injection Therapy With Fibrin Sealant Versus Endoscopic Ligature for Acute Hemostasis and the Prophylaxis of Recurrent Bleeding From Esophageal Varices Completed NCT00161915 Phase 3 Fibrin Sealant
26 A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis Recruiting NCT04365868 Phase 2, Phase 3 belapectin;Placebo
27 A Multi-center Randomized Controlled Study of Primary Prevention of Esophageal Variceal Bleeding in Cirrhotic Patients Treated With HVPG-guided Beta- Blocker Therapy or Standard Heart Rate-guided Beta-blocker Therapy Recruiting NCT01618890 Phase 3
28 Randomized Controlled Trial of Carvedilol Versus Endoscopic Band Ligation for Primary Prophylaxis of Oesophageal Variceal Bleeding in Cirrhotic Patients With Arterial Hypertension Recruiting NCT04499898 Phase 2, Phase 3 Carvedilol
29 Endoscopic Injection Sclerotherapy Versus N-butyl-2-cyanoacrylate Injection in the Management of Actively Bleeding Esophageal Varices Active, not recruiting NCT03388125 Phase 3 Injection Sclerotherapy;N-butyl-2-cyanoacrylate
30 Beta Blockers Versus Variceal Band Ligation and Beta Blockers for Primary Prophylaxis of Variceal Bleeding Terminated NCT00409084 Phase 3
31 A Phase 3 Study of Carvedilol vs Variceal Band Ligation vs Combination Therapy for Primary Prophylaxis of Variceal Bleeding Withdrawn NCT02066649 Phase 3 Carvedilol
32 A New Technique to Enhance Detection of Small Esophageal Varices by PillCam ESO Capsule Endoscopy Withdrawn NCT00911131 Phase 3
33 Evaluation of Gastroesophageal Varices in Cirrhotic and Non-cirrhotic Patients With Portal Hypertension by Transnasal Endoscopy. Unknown status NCT02767206
34 Evaluation of Blood Ammonia Level as a Non Invasive Predictor for Presence of Gastroesophageal Varices and Risk of Bleeding Unknown status NCT03212872
35 A Randomized Controlled Trial of Ligation Versus Ligation Plus Sclerotherapy in Addition to Cyanoacrylate in Patients With Gastroesophageal Varices Unknown status NCT01592578
36 Correlation of Platelets Count With Endoscopic Findings in a Cohort of Egyptian Patients With Liver Cirrhosis Unknown status NCT02621372
37 Predictive Factors and Outcome of Esophageal Ulcers After Endoscopic Treatment of Esophageal Varices; Multicenter Study Unknown status NCT02256046
38 Investigator Sponsored Study of Effects of Somatostatin on Post-endoscopic Portal Hemodynamic in Cirrhotic Patients With Esophageal Gastric Varices Unknown status NCT01426087 Somatostatin
39 A Single-center Randomized Controlled Study of Secondary Prophylaxis of Cirrhosis Related Esophagogastric Variceal Hemorrhage Treated With HVPG-guided Therapy or Standard Esophageal Variceal Ligation Plus Beta-blocker Unknown status NCT03687216
40 Post-balloon Occluded Retrograde Transvenous Obliteration Use of Propranolol for the Prevention of Worsening of Esophageal Varices in Patients With Isolated Gastric Varices Unknown status NCT03171805 Propranolol
41 Trial of Monthly Versus Bi-weekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding Unknown status NCT02719119
42 The Accuracy of Contrast Abdominal CT for the Detection of High-Grade Esophageal and Gastric Varices in Patients With Cirrhosis Completed NCT00587197
43 A Novel Disposable Transnasal Esophagoscope: a Prospective Pilot Trial of Feasibility, Safety and Tolerance Completed NCT01360515
44 Effective Haemostasis Using Self-expandable Covered Mesh-metal Oesophageal Stents Versus Standard Endoscopic Therapy in the Treatment of Oesophageal Variceal Haemorrhage: A Multicentre, Open, Prospective, Randomised, Controlled Study. Completed NCT01851564
45 A Double Blind Randomized Placebo-Controlled Trial of Somatostatin in Association With Endoscopic Variceal Ligation (EVL) in Control of Acute Variceal Bleeding Completed NCT01267669 Somatostatin;Placebo
46 Prognostic Value of Measuring DsAz by MRI in Cirrhotic Patients on Prophylactic Treatment With β Blocker (AzyMR) Completed NCT02475122
47 San Diego Bleeding Esophageal Varices Study Completed NCT00690027
48 Follow-up of Glypressin (Terlipressin) Clinical Efficacy in the Treatment of Bleeding Oesophageal Varices Completed NCT01335516
49 Treatment of Schistosomal Portal Hypertension: Assessment of Efficacy of Endoscopic Therapy Alone or in the Combined With Surgical Procedure Completed NCT01931826
50 A Randomized Controlled Trial of Monthly Versus Biweekly Endoscopic Variceal Ligation for the Prevention of Esophageal Variceal Rebleeding Completed NCT01809535

Search NIH Clinical Center for Esophageal Varix

Genetic Tests for Esophageal Varix

Genetic tests related to Esophageal Varix:

# Genetic test Affiliating Genes
1 Esophageal Varix 29

Anatomical Context for Esophageal Varix

MalaCards organs/tissues related to Esophageal Varix:

40
Liver, Spleen, Kidney, Heart, Bone, Thyroid, Colon

Publications for Esophageal Varix

Articles related to Esophageal Varix:

(show top 50) (show all 6485)
# Title Authors PMID Year
1
[Splanchnic hemodynamic effects of somatostatin and octreotide in cirrhotic patients. A Doppler ultrasonographic study]. 61 54
19025306 2008
2
Comparison of liver biopsy and transient elastography based on clinical relevance. 54 61
18818788 2008
3
Right liver lobe/albumin ratio: contribution to non-invasive assessment of portal hypertension. 54 61
17879402 2007
4
[Non-endoscopic predictors of large esophageal varices in patients with liver cirrhosis]. 54 61
17641556 2007
5
[Bleeding oesophageal varices--therapeutic options]. 61 54
17633875 2007
6
Coagulation abnormalities in cirrhotic patients with portal vein thrombosis. 61 54
18257465 2007
7
[The value of Doppler-ultrasonography and laboratory tests as non-invasive predictors of the presence of esophageal varices in patients with chronic liver disease]. 61 54
17047433 2006
8
[Non-invasive diagnosis of portal hypertension in cirrhosis. Application to the primary prevention of varices]. 54 61
16435503 2005
9
Review: somatostatin and its analogues do not reduce mortality in acute bleeding esophageal varices. 61 54
15989304 2005
10
Earlier recurrence of esophageal varices, following therapy, in patients with primary biliary cirrhosis (PBC) compared with non-PBC patients. 54 61
15580402 2004
11
Prevalence and predictors of esophageal varices in patients with primary sclerosing cholangitis. 61 54
14752839 2004
12
Two findings of portal hypertension: evaluation of correlation between serum-ascites albumin gradient and esophageal varices in non-alcoholic cirrhosis. 54 61
15048594 2003
13
[Vasoconstrictive Therapies for Bleeding Esophageal Varices and their Mechanisms of Action]. 61 54
14562199 2003
14
Review: Somatostatin analogues reduce blood products used in acute bleeding esophageal varices but do not reduce mortality. 61 54
12418833 2002
15
Risk factors for infections in cirrhotic patients with and without hepatocellular carcinoma. 54 61
12522534 2002
16
Prognosis of hepatocellular carcinoma associated with Child class B and C cirrhosis in relation to treatment: a multivariate analysis of 411 patients at a single center. 61 54
12483269 2002
17
Prognostic factors for survival in patients with compensated cirrhosis and small hepatocellular carcinoma after percutaneous ethanol injection therapy. 54 61
11443618 2001
18
Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection? 54 61
11172334 2001
19
[Drug therapy of hemorrhage in esophageal and gastric varices: role of vasoactive drugs]. 54 61
11291271 2000
20
Surgical indications for advanced hepatocellular carcinoma. 61 54
11020886 2000
21
[Sclerotherapy versus somatostatin in the treatment of upper digestive hemorrhage caused by rupture of esophageal varices]. 61 54
11236267 2000
22
Non-invasive diagnosis of esophageal varices in chronic liver diseases. 61 54
10580584 1999
23
Somatostatin or octreotide in acute variceal bleeding. 54 61
10207229 1999
24
Resource analysis of somatostatin in the treatment of bleeding esophageal varices. 61 54
10567787 1999
25
Benefit of prophylactic endoscopic sclerotherapy of esophageal varices. A retrospective analysis. 61 54
9602001 1998
26
Approach to the management of bleeding esophageal varices: role of somatostatin. 54 61
9603441 1998
27
[Gastroenterology. I: General gastroenterology]. 54 61
9499375 1997
28
Cirrhosis: a new, but expected cause of biliary sludge. 54 61
9046383 1997
29
[Molecular biology, pharmacology and signal transduction of 5 cloned human somatostatin receptors]. 54 61
9045539 1996
30
Terlipressin (glypressin) versus somatostatin in the treatment of bleeding esophageal varices--final report of a placebo-controlled, double-blind study. 54 61
8921578 1996
31
Prognostic value of the galactose test in predicting survival of patients with cirrhosis evaluated for liver transplantation. A prospective multicenter Italian study. AISF Group for the Study of Liver Transplantation. Associazione Italiana per lo Studio del Fegato. 61 54
8912146 1996
32
Hepatic resection of hepatocellular carcinoma in cirrhotic livers: is it unjustified in impaired liver function? 54 61
8693420 1996
33
Survival in alcoholic liver cirrhosis: prognostic value of portal pressure, size of esophageal varices and biochemical data. Comparison with Child classification. 61 54
8776835 1996
34
Predictive score for the development of hepatocellular carcinoma and additional value of liver large cell dysplasia in Western patients with cirrhosis. 61 54
8621142 1996
35
[Randomized trial and meta-analysis of somatostatin versus placebo in bleeding esophageal varices]. 54 61
8685994 1996
36
[Drug therapy of acute esophageal varices bleeding (vasopressin, terlipressin, somatostatin)]. 54 61
8571017 1995
37
A meta-analysis of somatostatin versus vasopressin in the management of acute esophageal variceal hemorrhage. 54 61
7557097 1995
38
Is somatostatin effective in the treatment of acute bleeding caused by esophageal varices? 54 61
7919564 1994
39
[Terlipressin and somatostatin in the treatment of hemorrhages from rupture of esophageal varices]. 61 54
7958662 1994
40
Albumin inhibits hemolysis of erythrocytes induced by ethanolamine oleate during endoscopic injection sclerotherapy. 61 54
8462932 1993
41
[Effectiveness of endoscopic sclerotherapy in the treatment of bleeding esophageal varices]. 54 61
8465042 1993
42
Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. 61 54
1426884 1992
43
Terlipressin vs. somatostatin in bleeding esophageal varices: a controlled, double-blind study. 61 54
1350562 1992
44
Somatostatin versus Sengstaken balloon tamponade for primary haemostasia of bleeding esophageal varices. A randomized pilot study. 54 61
1672539 1991
45
Randomized, double-blind, placebo-controlled trial of somatostatin for variceal bleeding. Emergency control and prevention of early variceal rebleeding. 54 61
1976563 1990
46
[Drug treatment of acute esophageal varices hemorrhage using vasoactive substances (somatostatin and octreotide)]. 61 54
1980776 1990
47
Comparison of somatostatin and vasopressin in bleeding esophageal varices. 61 54
1973591 1990
48
Factors of prognostic importance in primary biliary cirrhosis. 54 61
2305209 1990
49
Long-term kidney and liver outcome in 50 children with autosomal recessive polycystic kidney disease. 61
33165639 2021
50
Diagnostic accuracy of spleen stiffness to evaluate portal hypertension and esophageal varices in chronic liver disease: a systematic review and meta-analysis. 61
32974686 2021

Variations for Esophageal Varix

Expression for Esophageal Varix

Search GEO for disease gene expression data for Esophageal Varix.

Pathways for Esophageal Varix

Pathways related to Esophageal Varix according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.62 SERPINC1 SERPINA1 F3 F2
2 11.48 THPO SERPINA1 INS ALB AFP
3 10.57 INS F2 ALB AFP
4 10.46 INS GPT

GO Terms for Esophageal Varix

Cellular components related to Esophageal Varix according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 THPO SST SERPINC1 SERPINA1 INS IFNL3
2 extracellular exosome GO:0070062 9.92 SERPINC1 SERPINA1 PKHD1 HP GPT F2
3 blood microparticle GO:0072562 9.73 SERPINC1 HP F2 CP BCHE ALB
4 endoplasmic reticulum lumen GO:0005788 9.56 SERPINC1 SERPINA1 INS F2 CP BCHE
5 extracellular space GO:0005615 9.5 THPO SST SERPINC1 SERPINA1 INS IFNL3

Biological processes related to Esophageal Varix according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.8 THPO PKHD1 INS F2 CBX8
2 post-translational protein modification GO:0043687 9.65 SERPINC1 SERPINA1 CP ALB AFP
3 blood coagulation GO:0007596 9.62 SERPINC1 SERPINA1 F3 F2
4 response to nutrient GO:0007584 9.54 SST SERPINC1 BCHE
5 sodium ion export across plasma membrane GO:0036376 9.49 ATP4A ATP12A
6 cellular potassium ion homeostasis GO:0030007 9.48 ATP4A ATP12A
7 regulation of blood coagulation GO:0030193 9.46 SERPINC1 F2
8 hemostasis GO:0007599 9.46 SERPINC1 SERPINA1 F3 F2
9 establishment or maintenance of transmembrane electrochemical gradient GO:0010248 9.43 ATP4A ATP12A
10 acute-phase response GO:0006953 9.26 SERPINA1 INS HP F2
11 cellular protein metabolic process GO:0044267 9.17 SERPINC1 SERPINA1 INS F2 CP ALB

Molecular functions related to Esophageal Varix according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 sodium:potassium-exchanging ATPase activity GO:0005391 9.26 ATP4A ATP12A
2 potassium-transporting ATPase activity GO:0008556 9.16 ATP4A ATP12A
3 potassium:proton exchanging ATPase activity GO:0008900 8.96 ATP4A ATP12A
4 protease binding GO:0002020 8.92 SERPINC1 SERPINA1 INS F3

Sources for Esophageal Varix

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....